316 related articles for article (PubMed ID: 36959810)
21. Positron Emission Tomography-Derived Radiomics and Artificial Intelligence in Multiple Myeloma: State-of-the-Art.
Manco L; Albano D; Urso L; Arnaboldi M; Castellani M; Florimonte L; Guidi G; Turra A; Castello A; Panareo S
J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137738
[TBL] [Abstract][Full Text] [Related]
22. Development of Radiomic-Based Model to Predict Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.
Tankyevych O; Trousset F; Latappy C; Berraho M; Dutilh J; Tasu JP; Lamour C; Cheze Le Rest C
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497415
[TBL] [Abstract][Full Text] [Related]
23. Integrating Artificial Intelligence and PET Imaging for Drug Discovery: A Paradigm Shift in Immunotherapy.
McGale JP; Howell HJ; Beddok A; Tordjman M; Sun R; Chen D; Wu AM; Assi T; Ammari S; Dercle L
Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399425
[TBL] [Abstract][Full Text] [Related]
24. Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodules-a literature review.
Dahlsgaard-Wallenius SE; Hildebrandt MG; Johansen A; Vilstrup MH; Petersen H; Gerke O; Høilund-Carlsen PF; Morsing A; Andersen TL
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):584-591. PubMed ID: 32719914
[TBL] [Abstract][Full Text] [Related]
25. PET/CT Based EGFR Mutation Status Classification of NSCLC Using Deep Learning Features and Radiomics Features.
Huang W; Wang J; Wang H; Zhang Y; Zhao F; Li K; Su L; Kang F; Cao X
Front Pharmacol; 2022; 13():898529. PubMed ID: 35571081
[No Abstract] [Full Text] [Related]
26.
Polverari G; Ceci F; Bertaglia V; Reale ML; Rampado O; Gallio E; Passera R; Liberini V; Scapoli P; Arena V; Racca M; Veltri A; Novello S; Deandreis D
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32380754
[TBL] [Abstract][Full Text] [Related]
27. PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs.
Yang L; Xu P; Li M; Wang M; Peng M; Zhang Y; Wu T; Chu W; Wang K; Meng H; Zhang L
Front Oncol; 2022; 12():894323. PubMed ID: 35800046
[TBL] [Abstract][Full Text] [Related]
28. Current Evidence, Limitations and Future Challenges of Survival Prediction for Glioblastoma Based on Advanced Noninvasive Methods: A Narrative Review.
García-García S; García-Galindo M; Arrese I; Sarabia R; Cepeda S
Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556948
[No Abstract] [Full Text] [Related]
29. Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy.
Dercle L; McGale J; Sun S; Marabelle A; Yeh R; Deutsch E; Mokrane FZ; Farwell M; Ammari S; Schoder H; Zhao B; Schwartz LH
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36180071
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of Computed Tomography and/or
Moran A; Wang Y; Dyer BA; Yip SSF; Daly ME; Yamamoto T
Clin Lung Cancer; 2021 Sep; 22(5):461-468. PubMed ID: 33931316
[TBL] [Abstract][Full Text] [Related]
31. Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors.
Park C; Jeong DY; Choi Y; Oh YJ; Kim J; Ryu J; Paeng K; Lee SH; Ock CY; Lee HY
Front Immunol; 2022; 13():1038089. PubMed ID: 36660547
[TBL] [Abstract][Full Text] [Related]
32. Development and Validation of a Radiomics Nomogram Based on
Yang B; Zhong J; Zhong J; Ma L; Li A; Ji H; Zhou C; Duan S; Wang Q; Zhu C; Tian J; Zhang L; Wang F; Zhu H; Lu G
Front Oncol; 2020; 10():1042. PubMed ID: 32766134
[No Abstract] [Full Text] [Related]
33. The added value of artificial intelligence to LI-RADS categorization: A systematic review.
Laino ME; Viganò L; Ammirabile A; Lofino L; Generali E; Francone M; Lleo A; Saba L; Savevski V
Eur J Radiol; 2022 May; 150():110251. PubMed ID: 35303556
[TBL] [Abstract][Full Text] [Related]
34. Towards clinical application of image mining: a systematic review on artificial intelligence and radiomics.
Sollini M; Antunovic L; Chiti A; Kirienko M
Eur J Nucl Med Mol Imaging; 2019 Dec; 46(13):2656-2672. PubMed ID: 31214791
[TBL] [Abstract][Full Text] [Related]
35. A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts ALK Rearrangement Status in Lung Adenocarcinoma.
Chang C; Sun X; Wang G; Yu H; Zhao W; Ge Y; Duan S; Qian X; Wang R; Lei B; Wang L; Liu L; Ruan M; Yan H; Liu C; Chen J; Xie W
Front Oncol; 2021; 11():603882. PubMed ID: 33738250
[TBL] [Abstract][Full Text] [Related]
36. CT radiomics and PET radiomics: ready for clinical implementation?
Bogowicz M; Vuong D; Huellner MW; Pavic M; Andratschke N; Gabrys HS; Guckenberger M; Tanadini-Lang S
Q J Nucl Med Mol Imaging; 2019 Dec; 63(4):355-370. PubMed ID: 31527578
[TBL] [Abstract][Full Text] [Related]
37. Imaging Biomarkers in Thoracic Oncology: Current Advances in the Use of Radiomics in Lung Cancer Patients and its Potential Use for Therapy Response Prediction and Monitoring.
Kroschke J; von Stackelberg O; Heußel CP; Wielpütz MO; Kauczor HU
Rofo; 2022 Jul; 194(7):720-727. PubMed ID: 35211928
[TBL] [Abstract][Full Text] [Related]
38. Frontiers and hotspots of
Liu X; Hu X; Yu X; Li P; Gu C; Liu G; Wu Y; Li D; Wang P; Cai J
Front Oncol; 2022; 12():965773. PubMed ID: 36176388
[TBL] [Abstract][Full Text] [Related]
39. A review on advances in
Anan N; Zainon R; Tamal M
Insights Imaging; 2022 Feb; 13(1):22. PubMed ID: 35124733
[TBL] [Abstract][Full Text] [Related]
40. Using contrast-enhanced CT and non-contrast-enhanced CT to predict EGFR mutation status in NSCLC patients-a radiomics nomogram analysis.
Yang X; Liu M; Ren Y; Chen H; Yu P; Wang S; Zhang R; Dai H; Wang C
Eur Radiol; 2022 Apr; 32(4):2693-2703. PubMed ID: 34807270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
